Manipulation of microglial activation as a therapeutic strategy in Alzheimer's disease

Feng Shiun Shie, Randall (Randy) Woltjer

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the leading cause of dementia. Although the etiology of AD remains controversial, the amyloid hypothesis suggests that β-antyloid (Aβ) peptides may contribute to brain dysfunction, and microglial activation has become increasingly regarded as a potential contributor to disease pathogenesis. Microglial activation is characterized by morphological changes and by production of various effectors, and activated neuroinflammation concurrent with increased oxidative stress may contribute to damage to neurons. However, recently there has been a recognition that microglia may also play a neuroprotective role through their release of neurotrophic factors and through phagocytosis of Aβ. Thus, there is growing consensus that a favorable combination of diminished microglia-mediated neurainflammation and enhanced Aβ clearance may be critical in AD therapy. In this review, we will discuss the role of microglial activation in AD and how pharmacologic manipulation of microglia might bear upon the treatment of AD.

Original languageEnglish (US)
Pages (from-to)2865-2871
Number of pages7
JournalCurrent Medicinal Chemistry
Volume14
Issue number27
DOIs
StatePublished - Nov 2007

Fingerprint

Alzheimer Disease
Chemical activation
Microglia
Therapeutics
Nerve Growth Factors
Oxidative stress
Phagocytosis
Amyloid
Dementia
Consensus
Oxidative Stress
Neurons
Brain
Peptides

Keywords

  • Alzheimer's disease
  • Beta-amyloid
  • Microglial activation
  • Neuroinflammation
  • Tau
  • Therapy

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Manipulation of microglial activation as a therapeutic strategy in Alzheimer's disease. / Shie, Feng Shiun; Woltjer, Randall (Randy).

In: Current Medicinal Chemistry, Vol. 14, No. 27, 11.2007, p. 2865-2871.

Research output: Contribution to journalArticle

@article{7fd5cb0d065749fe8e040d2303ae8f75,
title = "Manipulation of microglial activation as a therapeutic strategy in Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is the leading cause of dementia. Although the etiology of AD remains controversial, the amyloid hypothesis suggests that β-antyloid (Aβ) peptides may contribute to brain dysfunction, and microglial activation has become increasingly regarded as a potential contributor to disease pathogenesis. Microglial activation is characterized by morphological changes and by production of various effectors, and activated neuroinflammation concurrent with increased oxidative stress may contribute to damage to neurons. However, recently there has been a recognition that microglia may also play a neuroprotective role through their release of neurotrophic factors and through phagocytosis of Aβ. Thus, there is growing consensus that a favorable combination of diminished microglia-mediated neurainflammation and enhanced Aβ clearance may be critical in AD therapy. In this review, we will discuss the role of microglial activation in AD and how pharmacologic manipulation of microglia might bear upon the treatment of AD.",
keywords = "Alzheimer's disease, Beta-amyloid, Microglial activation, Neuroinflammation, Tau, Therapy",
author = "Shie, {Feng Shiun} and Woltjer, {Randall (Randy)}",
year = "2007",
month = "11",
doi = "10.2174/092986707782359981",
language = "English (US)",
volume = "14",
pages = "2865--2871",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "27",

}

TY - JOUR

T1 - Manipulation of microglial activation as a therapeutic strategy in Alzheimer's disease

AU - Shie, Feng Shiun

AU - Woltjer, Randall (Randy)

PY - 2007/11

Y1 - 2007/11

N2 - Alzheimer's disease (AD) is the leading cause of dementia. Although the etiology of AD remains controversial, the amyloid hypothesis suggests that β-antyloid (Aβ) peptides may contribute to brain dysfunction, and microglial activation has become increasingly regarded as a potential contributor to disease pathogenesis. Microglial activation is characterized by morphological changes and by production of various effectors, and activated neuroinflammation concurrent with increased oxidative stress may contribute to damage to neurons. However, recently there has been a recognition that microglia may also play a neuroprotective role through their release of neurotrophic factors and through phagocytosis of Aβ. Thus, there is growing consensus that a favorable combination of diminished microglia-mediated neurainflammation and enhanced Aβ clearance may be critical in AD therapy. In this review, we will discuss the role of microglial activation in AD and how pharmacologic manipulation of microglia might bear upon the treatment of AD.

AB - Alzheimer's disease (AD) is the leading cause of dementia. Although the etiology of AD remains controversial, the amyloid hypothesis suggests that β-antyloid (Aβ) peptides may contribute to brain dysfunction, and microglial activation has become increasingly regarded as a potential contributor to disease pathogenesis. Microglial activation is characterized by morphological changes and by production of various effectors, and activated neuroinflammation concurrent with increased oxidative stress may contribute to damage to neurons. However, recently there has been a recognition that microglia may also play a neuroprotective role through their release of neurotrophic factors and through phagocytosis of Aβ. Thus, there is growing consensus that a favorable combination of diminished microglia-mediated neurainflammation and enhanced Aβ clearance may be critical in AD therapy. In this review, we will discuss the role of microglial activation in AD and how pharmacologic manipulation of microglia might bear upon the treatment of AD.

KW - Alzheimer's disease

KW - Beta-amyloid

KW - Microglial activation

KW - Neuroinflammation

KW - Tau

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=36749017492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749017492&partnerID=8YFLogxK

U2 - 10.2174/092986707782359981

DO - 10.2174/092986707782359981

M3 - Article

C2 - 18045132

AN - SCOPUS:36749017492

VL - 14

SP - 2865

EP - 2871

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 27

ER -